You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

357 Results
Drug
Other Name(s): Mektovi®
Jul 2023
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Metastatic, Persistent, or Recurrent Carcinoma of the Cervix
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Nov 2023
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - In Combination with Lenalidomide and Dexamethasone for Previously Untreated Multiple Myeloma Pre-SCT
ODB Limited Use
    lenalidomide - Induction therapy for transplant eligible, newly diagnosed multiple myeloma, according to clinical criteria
ODB - General Benefit
    dexamethasone
Dec 2023
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Intent: Palliative
Funding:
New Drug Funding Program
    Mogamulizumab - Relapsed or Refractory Mycosis Fungoides or Sezary Syndrome
May 2024
Drug
Other Name(s): Poteligeo®
May 2024
Document
The following information answers many of the questions primary care physicians commonly ask about the MyPractice Primary Care Physician Report and...

Pages